We are investigating possible false claims, accounting and reporting practices and breaches of fiduciary duty and violations of the federal securities laws by the Board of Directors and certain Company officers of CareDx, Inc. (NASDAQ: CDNA) (“CareDx” or the “Company”), which has led to investigations by the U.S. Department of Justice (“DOJ”) and the Securities and Exchange Commission (“SEC”) concerning “certain business practices related to [CareDx’s] kidney testing and phlebotomy services.”
On October 28, 2021, the Company filed a Form 10Q which disclosed that it had recently received a False Claims Act (“FCA”) civil investigative demand from the DOJ as well as a subpoena from the SEC related to the Company’s kidney testing and phlebotomy services “as well as certain of [CareDx’s] accounting and public reporting practices.” The Company also disclosed that an additional unnamed state regulatory agency has also made an information request, and it is possible that the Company will “receive additional requests for information from the DOJ, SEC, or other regulatory and governmental agencies regarding similar or related subject matters.”
WeissLaw LLP is investigating whether CareDx’s Board of Directors: failed to establish and maintain a comprehensive system of internal controls over certain of its kidney testing and phlebotomy services; failed to establish and maintain a comprehensive system of internal controls over its accounting and public reporting practices; and violated federal securities laws or breached fiduciary duties owed to CareDx and its shareholders.
If you own CDNA shares and wish to discuss this investigation, please visit our website at https://www.weisslaw.co/news-and-cases/cdna or contact Josh Rubin at email@example.com or (212) 682-3025. There is no cost or obligation to you.
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients. For more information about the firm, please go to: http://www.weisslaw.co
January 12, 2022
We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CyrusOne Inc. (“CyrusOne” or the “Company”) (NASDAQ:CONE), in connection with the proposed acquisition of the Company by Kohlberg Kravis Roberts & Co. L.P. (“KKR”), a leading global investment firm, and Global Infrastructure Partners (“GIP”). Under the terms of the acquisition agreement, the Company’s shareholders will receive $90.50 in cash for each share of CyrusOne common stock that they hold.
January 12, 2022
We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Falcon Minerals Corporation (“Falcon” or the “Company”) (NASDAQ: FLMN), in connection with the proposed merger of the Company with Desert Peak Minerals (“Desert Peak”). Under the terms of the merger agreement, Desert Peak will become a subsidiary of Falcon’s operating partnership (“OpCo”). The combined company will retain Falcon’s “Up-C” structure, and Desert Peak’s equity holders will receive 235 million shares of Class C common stock, with voting rights in the combined company and a corresponding number of limited partner units representing economic interests in OpCo.
January 11, 2022
We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Comunibanc Corp. (“Comunibanc” or the “Company”)(OTC: CBCZ) in connection with the proposed merger of the Company with Civista Bancshares, Inc. (“Civista”) (NASDAQ: CIVB). Under the terms of the merger agreement, Comunibanc shareholders will receive $30.13 in cash and 1.1888 shares of Civista common stock for each Comunibanc share that they own, representing implied merger consideration of $58.93 based upon Civista’s January 11, 2022 closing price of $24.23.